ClinicalTrials.gg
CompletedNCT01789281Updated Jun 11, 2021Results posted

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

A Phase 4 interventional study of Everolimus and Sandostatin LAR Depot in Neoplasms, sponsored by Novartis Pharmaceuticals. Completed at 24 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Study to allow access to everolimus for patients who are on everolimus treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator

Read the detailed description

This multi-center, open-label roll-over study aimed to better characterize the long-term safety of everolimus in subjects currently being treated in a Novartis-sponsored studies and who were receiving clinical benefit on the current study treatment as judged by the Investigator.

The study was designed to provide continued treatment with everolimus monotherapy to the subjects. Subjects were allowed to continue combination therapy with Sandostatin LAR® Depot if they were receiving this combination therapy on the parent protocol. Subjects were allowed to continue in this roll-over study until they no longer benefitted from the everolimus treatment as judged by the Investigator, discontinued due to toxicities, subject withdrew consent or lost to follow-up, disease progression, protocol non-compliance, or subject death, whichever occurred first. A subject was considered to have reached end of study when everolimus treatment was permanently discontinued.

As per the original protocol, it was designed to collect only serious adverse events (SAEs) and protocol defined adverse events of special interest (AESIs). However, due to the feedback received from health authorities, the protocol was amended in 2016 (3 years after study was initiated) to collect all AEs (non-serious and serious AEs, and AESIs). The protocol was also amended to include an Investigator assessment of clinical benefit at every visit for remaining subjects.

02

Conditions studied

  • Neoplasms

Keywords

  • Neoplasms
  • Carcinoid tumor
  • Neuroendocrine tumor
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 34 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject enrolled in a Novartis-sponsored, CD\&MA study receiving everolimus or everolimus plus Sandostatin LAR Depot and fulfilled all their requirements in the parent study
  • Subject benefiting from treatment with everolimus, as determined by the guidelines of the parent protocol.

Exclusion criteria

Exclusion Criteria:

  • Subject was permanently discontinued from everolimus study treatment in the parent study.
  • Subject was receiving everolimus in combination with an unapproved or experimental treatment

Other protocol-defined inclusion/exclusion criteria might apply

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Everolimus

    Participants who were receiving everolimus in a Novartis-sponsored study, were not progressing on the current study treatment and were unable to access everolimus treatment outside of a clinical trial. Participants receiving everolimus treatment in combination with Sandostatin LAR Depot on the parent protocol were allowed to continue Sandostatin LAR Depot treatment.

    Drug: Everolimus · Drug: Sandostatin LAR Depot

Interventions

  • Everolimus was provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. The starting dose of everolimus was the same as the last dose that was given in the parent study. Dose modification thereafter was done at the discretion of the Investigator based upon what is in the subject's best interest.

  • Sandostatin LAR Depot was provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections was the same as the last dose that was given in the parent study.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Any sign or symptom that occurs during the study treatment plus the 30 days post treatment. All SAEs were captured in safety database from enrollment. Safety data collection was changed in the protocol amendment released in March 2016: AEs and SAEs were captured in the clinical database from protocol amendment release (18 March 2016). Hence, SAEs from both safety database and clinical database are summarized separately.

    Time frame: SAEs collected in safety database from enrollment to end of treatment (EOT) plus 30 days, up to approximately 7.2 years. AEs/SAEs collected in clinical database from protocol amendment date 18 March 2016 to EOT plus 30 days, up to approximately 4.5 years

Secondary outcomes

  1. Percentage of Patients With Clinical Benefit

    Percentage of patients with clinical benefit as judged by the investigator. Investigator attestation of continued clinical benefit was collected in clinical database after protocol amendment (release date 18 March 2016). Clinical benefit assessment before protocol amendment was done retrospectively.

    Time frame: After 3 months from enrollment, every 3 months, until end of treatment, assessed up to 7.2 years

07

Results

Posted Jun 11, 2021
Limitations and caveats
The original protocol was designed to collect only SAEs and protocol defined AESIs in the Safety database. The protocol was amended in 2016 (3 years after study was initiated) to include all AEs (non-SAEs, SAEs, and AESIs) to be collected in the clinical database. At the time of amendment release, 32 of the 34 subjects were enrolled and did not have AEs collected in clinical database before protocol amendment, which also amounts to approximately 50% of SAEs not reported in clinical database.

Participant flow

There was no screening period. Patients enrolled into trial directly from the parent protocol.

Participant flow — Overall Study
MilestoneEverolimusEverolimus+Sandostatin LAR
Started2212
Completed02
Not completed2210
Withdrew: Disease progression154
Withdrew: Adverse event55
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up10
Withdrew: Administrative problems01

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Any sign or symptom that occurs during the study treatment plus the 30 days post treatment. All SAEs were captured in safety database from enrollment. Safety data collection was changed in the protocol amendment released in March 2016: AEs and SAEs were captured in the clinical database from protocol amendment release (18 March 2016). Hence, SAEs from both safety database and clinical database are summarized separately.

Time frame:
SAEs collected in safety database from enrollment to end of treatment (EOT) plus 30 days, up to approximately 7.2 years. AEs/SAEs collected in clinical database from protocol amendment date 18 March 2016 to EOT plus 30 days, up to approximately 4.5 years
Reported as:
Count of participants · Participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsEverolimusEverolimus+Sandostatin LAR
SAEs (Safety database)69
Treatment-related SAEs (Safety database)14
AEs (Clinical Database)77
Tretament-related AEs (Clinical Database)44
SAEs (Clinical Database)24
Treatment-related SAEs (Clinical Database)02
SecondaryPercentage of Patients With Clinical Benefit

Percentage of patients with clinical benefit as judged by the investigator. Investigator attestation of continued clinical benefit was collected in clinical database after protocol amendment (release date 18 March 2016). Clinical benefit assessment before protocol amendment was done retrospectively.

Time frame:
After 3 months from enrollment, every 3 months, until end of treatment, assessed up to 7.2 years
Reported as:
Count of participants · Participants
Percentage of Patients With Clinical Benefit
ParticipantsEverolimusEverolimus+Sandostatin LAR
At 3 months97
At 6 months87
At 9 months87
At 12 months87
At 15 months87
At 18 months87
At 21 months87
At 24 months67
At 27 months57
At 30 months37
At 33 months27
At 36 months17
At 39 months17
At 42 months16
At 45 months16
At 48 months16
At 51 months16
At 54 months06
At 57 months05
At 60 months05
At 63 months04
At 66 months04
At 69 months03
At 72 months03
At 75 months03
At 78 months02
At 81 months01
At 84 months00

Adverse events

Collected over SAEs were collected in safety database from enrollment to end of the treatment (EOT) plus 30 days, up to approximately 7.2 years. Other AEs (Non-serious AEs) were collected in clinical database from protocol amendment date 18 March 2016 to EOT plus 30 days, up to approximately 4.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus1/22 (4.5%)6/22 (27.3%)3/22 (13.6%)
Everolimus + Sandostatin LAR2/12 (16.7%)9/12 (75%)5/12 (41.7%)
All Subjects3/34 (8.8%)15/34 (44.1%)8/34 (23.5%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventEverolimusEverolimus + Sandostatin LARAll Subjects
PneumoniaInfections and infestations2/223/125/34
Cardiac failure congestiveCardiac disorders0/222/122/34
Acute kidney injuryRenal and urinary disorders0/222/122/34
Aplastic anaemiaBlood and lymphatic system disorders0/221/121/34
ThrombocytopeniaBlood and lymphatic system disorders0/221/121/34
Atrial fibrillationCardiac disorders0/221/121/34
Heart valve incompetenceCardiac disorders0/221/121/34
Abdominal painGastrointestinal disorders0/221/121/34
IleusGastrointestinal disorders0/221/121/34
NauseaGastrointestinal disorders0/221/121/34
Most frequent other events
Showing 10 of 46
Most frequent other events
EventEverolimusEverolimus + Sandostatin LARAll Subjects
Abdominal painGastrointestinal disorders0/223/123/34
NauseaGastrointestinal disorders0/222/122/34
VomitingGastrointestinal disorders0/222/122/34
Oedema peripheralGeneral disorders0/222/122/34
Decreased appetiteMetabolism and nutrition disorders0/222/122/34
HyperglycaemiaMetabolism and nutrition disorders0/222/122/34
Muscle spasmsMusculoskeletal and connective tissue disorders0/222/122/34
HeadacheNervous system disorders0/222/122/34
PneumonitisRespiratory, thoracic and mediastinal disorders2/220/122/34
AnaemiaBlood and lymphatic system disorders0/221/121/34

Baseline characteristics

Age, Continuous
Age, Continuous(Years)EverolimusEverolimus+Sandostatin LARTotal
Mean58.6 ± 9.5257.9 ± 11.3058.4 ± 10.02
Sex: Female, Male
Sex: Female, Male(Participants)EverolimusEverolimus+Sandostatin LARTotal
Female9615
Male13619
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)EverolimusEverolimus+Sandostatin LARTotal
Count of participants——0
08

Study locations

24 sites
  • Hematology Oncology Services of Arkansas SC
    Little Rock, Arkansas 72205, United States
  • Rocky Mountain Cancer Centers SC
    Greenwood Village, Colorado, United States
  • Stamford Hospital
    Stamford, Connecticut 06902, United States
  • H Lee Moffitt Cancer Center and Research Institute SC-2
    Tampa, Florida 33612, United States
  • Central Indiana Cancer Centers SC
    Indianapolis, Indiana 46227, United States
  • Crescent City Research Consortium, LLC SC-3
    Metairie, Louisiana 70006, United States
  • Mayo Clinic SC-2
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine Dept of Oncology
    Saint Louis, Missouri 63110, United States
  • Nebraska Cancer Specialists Onc Dept
    Omaha, Nebraska 68154, United States
  • Clinical Research Alliance
    Lake Success, New York 11042, United States
  • New York University Medical Center SC-4
    New York, New York 10016, United States
  • Oregon Health and Science University SC-8
    Portland, Oregon 97239, United States
  • Utah Cancer Specialists Utah Cancer (2)
    Salt Lake City, Utah 84106, United States
  • Novartis Investigative Site
    Praha 2, Czech Republic 120 00, Czechia
  • Novartis Investigative Site
    Arezzo, AR 52100, Italy
  • Novartis Investigative Site
    Milano, MI 20133, Italy
  • Novartis Investigative Site
    Milano, MI 20141, Italy
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03722, Korea, Republic of
  • Novartis Investigative Site
    Groningen, 9713 GZ, Netherlands
  • Novartis Investigative Site
    Leningrad Region, Russia 188663, Russian Federation
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Izmir, 35040, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2013 to primary completion in Aug 2020, 87 months.

Results were first posted in Jun 2021, 9 months after primary completion.

Of 88 phase 4 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 64. This study's 87 months is above that.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2013
First posted
Feb 12, 2013
StartActual
May 14, 2013
Primary completionActual
Aug 28, 2020
CompletionActual
Aug 28, 2020
Results first posted
Jun 11, 2021
Last update
Jun 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01789281
Responsible party
Sponsor
First posted
Feb 12, 2013
Start date
May 14, 2013
Primary completion
Aug 28, 2020
Completion
Aug 28, 2020
Results posted
Jun 11, 2021
Last update
Jun 11, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion